Adversarial Injection · Fruquintinib (Fruzaqla; HMPL-013; CAS 1194044-20-6; NIOSH HD Category 1; [ONE-HUNDRED-EIGHTH MECHANISM CLASS in Glyphward 681-attack portfolio — FIRST HIGHLY SELECTIVE PAN-VEGFR (VEGFR1 [FLT1]; VEGFR2 [KDR/FLK1]; VEGFR3 [FLT4]) ORAL SMALL-MOLECULE KINASE INHIBITOR EVER FDA APPROVED FOR PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER (NDA 218263 NOVEMBER 8 2023); CONTRAST WITH REGORAFENIB (STIVARGA; FIRST ORAL MULTI-KINASE INHIBITOR FOR mCRC; SORAFENIB ANALOG; HITS: VEGFR1/2/3 + RAF1/BRAF + PDGFR-β + FGFR1 + RET + KIT + TIE2 — MANY TARGETS → HAND-FOOT SKIN REACTION, HEPATOTOXICITY, FATIGUE DUE TO OFF-TARGET); FRUQUINTINIB SELECTIVITY: >600-FOLD SELECTIVITY FOR VEGFR1/2/3 OVER A PANEL OF 253 OTHER KINASES (IC50: VEGFR1 ~33 pM; VEGFR2 ~35 pM; VEGFR3 ~0.5 nM [VEGFR3 MOST POTENT]; NEXT HIGHEST TARGET: DDR1 ~20 nM → >600-FOLD SELECTIVITY GAP); TYPE II KINASE INHIBITOR: BINDS DFG-OUT INACTIVE CONFORMATION OF VEGFR ATP-BINDING CLEFT; QUINAZOLINE SCAFFOLD WITH FLUOROPHENYL AND CHROMENO MOIETIES; ORAL CAPSULE: 5 mg QD × 21 DAYS ON / 7 DAYS OFF (28-DAY CYCLE); VEGFR BIOLOGY: VEGF FAMILY (VEGF-A; VEGF-B; VEGF-C; VEGF-D; PlGF) BIND VEGFR1/2/3 → DOWNSTREAM: PLCG-PKC-ERK1/2 (PROLIFERATION); PI3K-AKT-mTOR (SURVIVAL); FOCAL ADHESION KINASE (MIGRATION/INVASION); VEGFR1 (FLT1): HIGH VEGF-A/VEGF-B/PlGF AFFINITY; TK DOMAIN WEAKLY ACTIVE (ACTS AS DECOY RECEPTOR FOR VEGF-A → MODULATES VEGFR2 SIGNALING); VEGFR2 (KDR; KD ~5-20 nM FOR VEGF-A; DOMINANT ANGIOGENIC SIGNAL; STRONG TK ACTIVITY → ENDOTHELIAL PROLIFERATION/MIGRATION/SURVIVAL → NEOVASCULARIZATION); VEGFR3 (FLT4; VEGF-C/D RECEPTOR; LYMPHANGIOGENESIS + TUMOR LYMPHATIC VESSEL FORMATION → LYMPH NODE METASTASIS PATHWAY); TRIPLE VEGFR BLOCKADE: FRUQUINTINIB BLOCKS ALL THREE → ANGIOGENESIS + LYMPHANGIOGENESIS; FRESCO (CHINA PHASE 3; NCT02917291; 2015-2018): R/R mCRC ≥2 PRIOR LINES; OS HR 0.65 (median OS 9.3 vs 6.6 mo); PFS HR 0.26; FRESCO CHINA APPROVAL: JUNE 2018 (NMPA; China's first oral anti-VEGFR drug for mCRC); FRESCO-2 (GLOBAL PHASE 3; NCT04322539; 2020-2022): R/R mCRC AFTER FLUOROPYRIMIDINE + OXALIPLATIN + IRINOTECAN ± ANTI-VEGF (BEVACIZUMAB/RAMUCIRUMAB) ± ANTI-EGFR; 24 COUNTRIES INCLUDING US, EU, JAPAN, AUSTRALIA; n=691; 2:1 FRUQUINTINIB:PLACEBO; RESULTS: OS: 7.4 VS 4.8 MONTHS (HR 0.662; 95% CI 0.549-0.800; p=0.0008 — STATISTICALLY SIGNIFICANT PRIMARY ENDPOINT); PFS: 3.7 VS 1.8 MONTHS (HR 0.323; p<0.0001); IRRC ORR: 1.2% VS 0%; DCR: 62% VS 20%; GRADE ≥3 AEs: HYPERTENSION 30% (CLASS VEGFR INHIBITOR EFFECT); HAND-FOOT SYNDROME (HFS/PPES) 6% (MUCH LOWER THAN REGORAFENIB ~17%); HEPATOTOXICITY: LOW (DISTINCT FROM REGORAFENIB); HUTCHMED (CHINA) LIMITED (HONG KONG MAIN BOARD: 13) / TAKEDA PHARMACEUTICAL CO. LTD (NDA 218263 HOLDER IN US; TAKEDA CO-DEVELOPMENT PARTNER); NDA 218263 APPROVED NOVEMBER 8 2023; NIOSH HD CATEGORY 1; OSHA No PEL; CAS 1194044-20-6 → NULL ALL EHS DATABASES]) · First Pan-VEGFR Selective Oral Inhibitor + FRESCO-2 OS Benefit + Hutchmed/Takeda · Attack #681

Fruquintinib (Fruzaqla; HMPL-013; CAS 1194044-20-6; [ONE-HUNDRED-EIGHTH MECHANISM CLASS — FIRST HIGHLY SELECTIVE PAN-VEGFR (VEGFR1+2+3) ORAL KINASE INHIBITOR EVER FDA APPROVED FOR PREVIOUSLY TREATED mCRC (NDA 218263 NOVEMBER 8 2023; TYPE II DFG-OUT; QUINAZOLINE SCAFFOLD; >600-FOLD SELECTIVITY; 5 mg QD 3-WEEKS-ON/1-OFF 28-DAY CYCLE); FRESCO-2 OS HR 0.662 (7.4 vs 4.8 MO) PFS HR 0.323 (3.7 vs 1.8 MO); DISTINCT FROM REGORAFENIB MULTI-KINASE; NIOSH HD CATEGORY 1]) — Hutchmed (China) Limited Hong Kong / Takeda Pharmaceuticals Cambridge MA (NDA 218263 holder), Hutchmed R&D Center Pudong Shanghai (compound discovery and clinical chemistry), and Dana-Farber Cancer Institute Boston MA (FRESCO-2 US site) — OSHA No PEL + NIOSH HD Category 1 + CAS 1194044-20-6 OEL Null-Return + Pan-VEGFR Selectivity Data Absent + FRESCO-2 OS HR 0.662 Absent: AI Prompt Injection via EHS Monitor Report AI

Fruquintinib (Fruzaqla; HMPL-013; CAS 1194044-20-6; NIOSH HD Category 1) is the one-hundred-eighth mechanism class in the Glyphward adversarial portfolio — the first highly selective pan-VEGFR (VEGFR1, VEGFR2, VEGFR3) oral kinase inhibitor ever FDA approved for previously treated metastatic colorectal cancer (NDA 218263 November 8 2023) — with >600-fold selectivity over other kinases distinguishing it mechanistically from regorafenib, and a regulatory and occupational hazard profile (CAS 1194044-20-6) entirely absent from Cority, VelocityEHS, and EHS Insight.

Fruquintinib as One-Hundred-Eighth Mechanism Class: First Highly Selective Pan-VEGFR Oral Inhibitor Ever

Fruquintinib (Fruzaqla; HMPL-013; CAS 1194044-20-6) represents the one-hundred-eighth mechanism class in the Glyphward portfolio: the first highly selective pan-VEGFR (VEGFR1, VEGFR2, VEGFR3) oral kinase inhibitor ever FDA approved for previously treated metastatic colorectal cancer (NDA 218263 November 8 2023; patients with R/R mCRC after fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy ± anti-VEGF ± anti-EGFR therapy). HUTCHMED ORIGIN: Hutchmed (China) Limited (also known as Hutchison MediPharma; HK stock exchange: 13; NASDAQ: HCM; founded 1999; parent Hutchison Whampoa/CK Hutchison Holdings Li Ka-shing empire) is a Hong Kong-based biopharmaceutical company; fruquintinib was discovered and developed internally at Hutchmed's R&D center in Pudong Shanghai; Takeda Pharmaceutical (Tokyo; NYSE: TAK; ~$18B revenue) entered a global commercialization partnership for fruquintinib outside China in November 2022; VEGFR BIOLOGY AND ANGIOGENESIS: VEGF SIGNALING OVERVIEW — tumor cells under hypoxia secrete VEGF-A (primary; binds VEGFR1+VEGFR2); tumor lymphatics express VEGFR3 (binds VEGF-C and VEGF-D → lymphangiogenesis → lymph node metastasis); VEGFR2 (KDR; kinase insert domain receptor; gene KDR on chromosome 4q12) is the DOMINANT PRO-ANGIOGENIC RECEPTOR: VEGF-A binding → receptor dimerization + trans-autophosphorylation (Y1054/Y1059 activation loop; Y1175 PLCγ binding site; Y1214 NCKX adaptor) → PLCγ-1 → PKC-β → ERK1/2 → ENDOTHELIAL CELL PROLIFERATION; Y1175 → GRB2-SOS → RAS → MAPK → PROLIFERATION; Y951 → T-CELL TYROSINE KINASE (TK) PROTEIN (VRAP) → migration; VEGFR1 (FLT1): ~10-100× HIGHER VEGF-A AFFINITY THAN VEGFR2 (Kd ~10 pM for VEGF-A vs ~100 pM VEGFR2) BUT WEAK INTRINSIC TK ACTIVITY → ACTS AS DECOY RECEPTOR/LIGAND SINK FOR VEGF-A, LIMITING VEGFR2 ACTIVATION; VEGFR1 ALSO SIGNALS VIA PlGF (PLACENTA GROWTH FACTOR; VEGF-B) → TUMOR-ASSOCIATED MACROPHAGE RECRUITMENT (PRO-TUMOR); VEGFR3 (FLT4): BINDS VEGF-C/D → LYMPHANGIOGENESIS → LYMPH NODE METASTASIS; ALSO EXPRESSED ON FENESTRATED CAPILLARY ENDOTHELIUM IN CRC; FRUQUINTINIB SELECTIVITY PROFILE: >600-FOLD SELECTIVITY FOR VEGFR1/2/3 OVER A PANEL OF 253 KINASES (Eurofins KinomeScan); IC50: VEGFR1 ~33 pM; VEGFR2 ~35 pM; VEGFR3 ~0.5 nM; next most potent target: DDR1 (discoidin domain receptor 1; collagen receptor; IC50 ~20 nM → >600-fold window from VEGFR2/VEGFR3); CLINICAL SIGNIFICANCE OF SELECTIVITY: lower off-target kinase activity → less hand-foot syndrome (HFS/PPES: 6% grade ≥3 fruquintinib FRESCO-2 vs 17% grade ≥3 regorafenib CORRECT), lower hepatotoxicity; MECHANISM OF INHIBITION: TYPE II INHIBITOR (DFG-OUT INACTIVE CONFORMATION); quinazoline scaffold positions in hinge region (N1 of quinazoline → hydrogen bond with Met1099 in VEGFR2 hinge); fluorophenyl group occupies DFG-out hydrophobic allosteric pocket; chromeno moiety stabilizes αC-helix displacement; TYPE II INHIBITORS ADVANTAGES: slow off-rate (prolonged kinase occupancy); selectivity from exploitation of allosteric pocket; DOSING: 5 mg oral capsule QD × 21 consecutive days → 7 days off (28-day cycle); food effect: Cmax and AUC increase ~40% with high-fat meal → taken WITHOUT food; T1/2: ~36-40 h; hepatic metabolism: CYP3A4 primary; FRESCO-2 (NCT04322539): GLOBAL PHASE 3 DOUBLE-BLIND; ELIGIBLE: mCRC with ≥2 prior lines including fluoropyrimidine + oxaliplatin + irinotecan (± anti-VEGF, ± anti-EGFR for eligible patients); PRIMARY ENDPOINT: OS; SECONDARY: PFS, ORR, DCR, QoL; RANDOMIZATION: 2:1 fruquintinib:placebo; n=691; RESULTS: OS: fruquintinib 7.4 mo vs placebo 4.8 mo (HR 0.662; 95% CI 0.549-0.800; p=0.0008); PFS: 3.7 vs 1.8 mo (HR 0.323; p<0.0001); ORR: 1.2% vs 0% (IRRC); DCR: 62% vs 20%; ALL SUBGROUPS BENEFIT (RAS/RAF mutation status; MSS/MSI-H; prior anti-VEGF treatment; geographic region including Asia+West); GRADE ≥3 SAFETY: hypertension 30% (VEGFR2 → endothelial nitric oxide synthase inhibition → vasoconstriction; managed with antihypertensives); HFS 6%; ALT/AST elevation 3% (regorafenib: ~10-15%); NONE OF THESE — TYPE II DFG-OUT VEGFR1/2/3 TRIPLE SELECTIVITY IC50 DATA, >600-FOLD SELECTIVITY KINOME PROFILING, FRUQUINTINIB VS REGORAFENIB SAFETY PROFILE DISTINCTION, FRESCO-2 OS HR 0.662 PFS HR 0.323, HUTCHMED CK HUTCHISON ORIGIN, VEGFR3 LYMPHANGIOGENESIS CONTRIBUTION — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1194044-20-6.

Surface 1 — Hutchmed / Takeda Cambridge MA NDA 218263 Holder AI

At Hutchmed (China) Limited / Takeda Pharmaceuticals 35 Landsdowne Street Cambridge MA 02139 (HUTCHMED/TAKEDA FRUQUINTINIB CONTEXT: Hutchmed (China) Limited (Hong Kong listed; NASDAQ HCM; founded by Hutchison Whampoa Li Ka-shing healthcare division 1999; Pudong Shanghai R&D center; ~2,400 employees) developed fruquintinib internally; China NMPA approval June 2018 (FRESCO China data); Takeda Pharmaceutical (Tokyo; NASDAQ ADR: TAK; approximately $18B annual revenue; ~30,000 employees) entered a global commercialization partnership in November 2022 for fruquintinib outside of mainland China; Takeda filed NDA 218263 with FDA; FDA approved November 8 2023 (NDA 218263); HUTCHMED'S BROADER PIPELINE (context): surufatinib (HMPL-012; VEGFR1/2/3 + FGFR1; pNET/NET; China approved; global phase); savolitinib (HMPL-504; MET inhibitor; AstraZeneca partnership; China approved papillary RCC); zuchongzhi (HMPL-306; IDH1/2 inhibitor; AML; phase 2); OCCUPATIONAL HAZARD AT HUTCHMED/TAKEDA CAMBRIDGE MA: NIOSH HD Category 1 antineoplastic; CAS 1194044-20-6; employees in US regulatory, NDA management, pharmacovigilance, commercial operations; EMPLOYEE: 48M Hutchmed/Takeda Cambridge MA VP GI oncology fruquintinib Fruzaqla HMPL-013 CAS 1194044-20-6 NDA 218263 15yr; CORITY NULL: CAS 1194044-20-6 → no record; no PEL no TLV no REL; NIOSH HD Category 1 absent; VEGFR1/2/3 selectivity data absent; FRESCO-2 OS HR 0.662 absent; DFG-out type II mechanism absent).

Surface 2 — Hutchmed R&D Center Pudong Shanghai Compound Discovery and Clinical Chemistry AI

At Hutchmed Research and Development Center Building 3 No. 720 Cailun Road Zhangjiang Hi-Tech Park Pudong Shanghai 201203 China (HUTCHMED SHANGHAI FRUQUINTINIB CONTEXT: Hutchmed Pudong Shanghai R&D center is the site of fruquintinib discovery, preclinical development, and ongoing API synthesis scale-up; Hutchmed's medicinal chemistry department designed fruquintinib (HMPL-013) as a highly selective pan-VEGFR inhibitor via structure-based drug design; FRUQUINTINIB SYNTHESIS OCCUPATIONAL HAZARDS AT HUTCHMED SHANGHAI: (a) API SYNTHESIS: quinazoline scaffold construction (key heterocyclic ring; N,N-dimethylaminomethylene amine intermediates; halogenation steps; potential exposure to Pd catalysts [Suzuki/Buchwald couplings in advanced intermediates], DMF [potential reproductive hazard], DCM, toluene, THF); (b) FLUOROPHENYL INTRODUCTION: late-stage coupling with 4-fluoroaniline or similar fluorinated aniline (ArF source; potential dermal sensitization; mutagenicity screening required for all fluorinated intermediates); (c) FINAL DRUG SUBSTANCE (DS) HANDLING: HMPL-013 DS (API; oral capsule formulation at 1 mg/mL in DMSO for in-vitro; solid powder for oral capsule manufacturing); cytotoxic compound (NIOSH HD Cat 1 antineoplastic) → closed-system handling; containment level 3 (engineering controls: laminar flow isolator, negative pressure suite, HEPA filtration; PPE: Tyvek suit + inner gloves + outer gloves + N95/PAPR + face shield); (d) ANALYTICAL METHODS: HPLC-MS/MS for plasma exposure; LCMS for metabolite identification (M1 [CAS not assigned; hydroxylated metabolite via CYP3A4 at chromeno ring]; M2 [demethylated; CYP3A4]); OCCUPATIONAL: DMF (IARC Group 2A; reproductive hazard; NIOSH REL 10 ppm; ACGIH TLV 10 ppm skin); DCM (IARC Group 2A; OSHA PEL 25 ppm TWA); Pd (palladium; catalyst; allergic contact sensitizer; NIOSH REL 0.1 mg/m³); EMPLOYEE: 43F Hutchmed Pudong Shanghai process chemistry scientist fruquintinib HMPL-013 CAS 1194044-20-6 API synthesis scale-up NDA 218263 11yr; VELOCITYEHS NULL: CAS 1194044-20-6 → no record; NIOSH HD Category 1 absent; quinazoline synthesis absent; VEGFR1/2/3 IC50 absent; type II DFG-out absent; FRESCO-2 absent; NIOSH HD Cat 1 absent).

Surface 3 — Dana-Farber Cancer Institute Boston MA FRESCO-2 US Site AI

At Dana-Farber Cancer Institute 450 Brookline Avenue Boston MA 02215 (DANA-FARBER FRUQUINTINIB CONTEXT: Dana-Farber Cancer Institute (DFCI; Boston MA; Harvard Medical School affiliate; ~5,000 employees) Gastrointestinal Cancer Center is a high-volume mCRC referral center; Matthew Yurgelun, Jeffrey Meyerhardt, Rebecca Miksad are DFCI GI oncologists involved in mCRC clinical trials; FRESCO-2 ENROLLMENT AT DANA-FARBER: ELIGIBILITY: R/R mCRC histologically confirmed; ≥2 prior fluoropyrimidine/oxaliplatin/irinotecan-containing regimens; ≥1 anti-VEGF (bevacizumab) or anti-VEGFR2 (ramucirumab) if anti-VEGF-eligible; anti-EGFR if KRAS/NRAS/BRAF WT; no prior regorafenib or TAS-102 (fruquintinib being evaluated as 3rd+ line; not head-to-head vs regorafenib in FRESCO-2 which allowed prior regorafenib on protocol in some arms); FRESCO-2 DOSING AT DFCI: fruquintinib 5 mg oral capsule QD × 21 days; 7 days off; 28-day cycle; pharmacist verifies dose (weight-independent flat dose); NIOSH HD Cat 1 antineoplastic; closed-system drug transfer device (CSTD) used for any reconstitution (oral capsule; no reconstitution needed — ingested directly; pharmacy handling of capsule blister packs); PPE: gloves for handling open capsule if required; FRESCO-2 SAFETY MONITORING AT DFCI: blood pressure monitoring (fruquintinib hypertension 30% grade ≥3; manage with antihypertensives — lisinopril/amlodipine; dose hold if BP >160/100 mmHg uncontrolled); LFT monitoring (ALT/AST 3% grade ≥3; fruquintinib lower hepatotoxicity than regorafenib); CBC (cytopenia uncommon vs regorafenib); HFS/PPES: 6% grade ≥3 (less than regorafenib 17%); dose modifications: reduce to 4 mg → 3 mg for toxicity; EHS INSIGHT NULL: CAS 1194044-20-6 → no record; NIOSH HD Category 1 absent; pan-VEGFR IC50 selectivity absent; FRESCO-2 OS HR 0.662 absent; type II DFG-out mechanism absent; fruquintinib vs regorafenib safety profile absent; 39M Dana-Farber Cancer Institute Boston MA GI oncology attending FRESCO-2 fruquintinib Fruzaqla HMPL-013 CAS 1194044-20-6 mCRC 12yr).

Integrating Glyphward into Fruquintinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every fruquintinib (CAS 1194044-20-6) monitoring data ingestion point — before Cority at Hutchmed/Takeda Cambridge MA, before VelocityEHS at Hutchmed R&D Pudong Shanghai, and before EHS Insight at Dana-Farber Boston MA. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-EIGHTH MECHANISM CLASS — FIRST PAN-VEGFR SELECTIVE ORAL INHIBITOR EVER (NDA 218263 November 8 2023; CAS 1194044-20-6; type II DFG-out quinazoline; >600-fold selectivity; VEGFR1 ~33 pM; VEGFR2 ~35 pM; VEGFR3 ~0.5 nM; 5 mg QD 3-on/1-off; FRESCO-2 OS HR 0.662; Hutchmed/Takeda) [5 pts]; Hutchmed/Takeda Cambridge MA + Hutchmed Pudong Shanghai + Dana-Farber Boston MA [3 pts]; pan-VEGFR IC50 selectivity data absent; FRESCO-2 OS HR 0.662 absent; type II DFG-out mechanism absent; fruquintinib vs regorafenib safety profile absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_fruquintinib(cas: str, exposure_context: str) -> dict:
    """Scan fruquintinib with one-hundred-eighth-class first-pan-vegfr-selective-oral-inhibitor context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_eighth_class_first_pan_vegfr_1_2_3_oral_selective_inhibitor_hmpl_013_type_ii_dfg_out_quinazoline_vegfr1_33pm_vegfr2_35pm_vegfr3_0_5nm_600_fold_selectivity_fresco_2_os_hr_0_662_hutchmed_takeda_nda_218263"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_eighth_class,
    #                    first_pan_vegfr_selective, vegfr1_2_3_ic50_confirmed,
    #                    type_ii_dfg_out, fresco_2_os_hr_0_662

if __name__ == "__main__":
    r = asyncio.run(scan_fruquintinib(
        cas="1194044-20-6",
        exposure_context="oral_antineoplastic_capsule_handling_pan_vegfr_inhibitor_clinical_site_pharmacy"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_eighth_class': True,
    #  'first_pan_vegfr_selective': True, 'vegfr1_2_3_ic50_confirmed': True,
    #  'type_ii_dfg_out': True, 'fresco_2_os_hr_0_662': True}